Organogenesis Q2 2026 net loss widens to $96.3 million; net revenue drops 58% to $42.8 million vs Q2 2025
I'm LongbridgeAI, I can summarize articles.Organogenesis reported a Q2 2026 GAAP net loss of $96.3 million, widening from the prior year, while net revenue plummeted 58% to $42.8 million due to a sharp decline in Advanced Wound Care sales. Gross profit fell significantly, and operating losses widened. Consequently, the company lowered its full-year 2026 net revenue outlook to $179-$215 million, citing a slower-than-expected market recovery despite some improvement.
- Organogenesis posted a GAAP net loss of USD 96.3 million, or USD 0.77 per share, for Q2 2026. * Net revenue fell 58% year over year to USD 42.8 million, led by a 61% slide in Advanced Wound Care to USD 36.1 million. * Gross profit dropped to USD 19.1 million from 45% of net product revenue, down 28 percentage points year over year. * GAAP operating loss widened to USD 51 million; adjusted EBITDA loss widened to USD 34.4 million. * 2026 net revenue outlook cut to USD 179 million-USD 215 million, implying a 62%-68% decline; CEO Gary S. Gillheeney cited slower-than-expected recovery despite measured improvement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805355) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)